Allogene Therapeutics Announces November and December 2020 Virtual Investor Conference Participation
November 12 2020 - 8:30AM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) therapies for cancer, today announced that
management plans to participate in four investor conferences
through the end of the year.
Stifel 2020 Virtual Healthcare ConferenceMonday, November 16,
20201:00PM PT/4:00PM ET
Jefferies Virtual London Healthcare ConferenceTuesday, November
17, 202010:45AM PT/1:45PM ET/6:45PM GMT
Piper Sandler 32nd Annual Virtual Healthcare
ConferenceWednesday, December 2, 202010:00AM PT/1:00PM ET
The JMP Securities Hematology SummitTuesday, December 15,
20207:30AM PT/10:30AM ET*
These presentations will be webcast and made available on the
Company's website at www.allogene.com under the Investors tab
in the News and Events section (https://ir.allogene.com/events).
Following the live audio webcast, a replay will be available on the
Company's website for approximately 30 days.
*This is a preliminary presentation time. Please check our
website for the most up to date presentation time.
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the
development of allogeneic chimeric antigen receptor T cell
(AlloCAR T™) therapies for cancer. Led by a management team with
significant experience in cell therapy, Allogene is developing
a pipeline of “off-the-shelf” CAR T cell therapy candidates
with the goal of delivering readily available cell therapy
on-demand, more reliably, and at greater scale to more
patients. For more information, please visit www.allogene.com,
and follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements for
AllogeneThis press release contains forward-looking
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. The press release
may, in some cases, use terms such as "predicts," "believes,"
"potential," "proposed," "continue," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "will,"
"should" or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things: the ability to develop allogeneic
CAR T therapies for cancer and the potential benefits of AlloCAR T
therapy. Various factors may cause differences between Allogene’s
expectations and actual results as discussed in greater detail in
Allogene’s filings with the SEC, including without limitation in
its Form 10-Q for the quarter ended September 30, 2020. Any
forward-looking statements that are made in this press release
speak only as of the date of this press release. Allogene assumes
no obligation to update the forward-looking statements whether as a
result of new information, future events or otherwise, after the
date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:Christine
CassianoChief Communications Officer(714)
552-0326Christine.Cassiano@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Sep 2023 to Sep 2024